Gene · 3914
Papers1,750
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,750
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. | PLoS One | 2025 | 40036189 | PubTator, text mining | PubMed |
| Recombinant human collagen XVII protects skin basement membrane integrity by inhibiting the MAPK and Wnt signaling pathways. | Mol Med Rep | 2025 | 39981899 | PubTator, text mining | PubMed |
| Efficient Dual Cas9 Nickase Correction of a Prevalent Pathogenic LAMB 3 Variant for Junctional Epidermolysis Bullosa. | JID Innov | 2025 | 39944129 | PubTator, text mining | PubMed |
| Identification of deep intronic variants in junctional epidermolysis bullosa using genome sequencing and splicing assays. | NPJ Genom Med | 2025 | 39915495 | PubTator, text mining | PubMed |
| 3D bioprinting lobule-like hepatorganoids with induced vascularization for orthotopic implantation. | Mater Today Bio | 2025 | 39911370 | PubTator, text mining | PubMed |
| An Innovative Anoikis Signature With Inflammatory Infiltrates in Osteoarthritis. | Int J Rheum Dis | 2025 | 39895467 | PubTator, text mining | PubMed |
| Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39798821 | PubTator, text mining | PubMed |
| Prevalence of Crown Resorption in Amelogenesis Imperfecta due to Junctional Epidermolysis Bullosa. | Oral Dis | 2025 | 39777984 | PubTator, text mining | PubMed |
| Alterations in the microenvironment of junctional epidermolysis bullosa keratinocytes: A gene expression study. | Matrix Biol | 2025 | 39615637 | PubTator, text mining | PubMed |
A Missense Variant Affecting the N-Terminal Domain of the Laminin-332 β3 Chain Results in a Distinct Form of Junctional Epidermolysis Bullosa With Altered Granulation Tissue Response and No New Blistering: A Second Family Report. | Pediatr Dermatol | 2025 | 39443834 | PubTator, text mining | PubMed |
| Identification of a novel variant of LAMB3 in a patient with a distinct junctional epidermolysis bullosa laryngo-onycho-cutaneous syndrome phenotype. | Clin Exp Dermatol | 2025 | 39420565 | PubTator, text mining | PubMed |
| An intronic variant in LAMB3 contributes to junctional epidermolysis bullosa and enamel hypoplasia via translational attenuation. | Arch Oral Biol | 2025 | 39357391 | PubTator, text mining | PubMed |
| Molecular profiling of a cohort with epidermolysis bullosa in India: a single centre experience. | Clin Exp Dermatol | 2025 | 39141798 | PubTator, text mining | PubMed |
| Expression Profiling of Coding and Noncoding RNAs in the Endometrium of Patients with Endometriosis. | Int J Mol Sci | 2024 | 39408909 | PubTator, text mining | PubMed |
| Special Issue "Bioinformatics Study in Human Diseases: Integration of Omics Data for Personalized Medicine". | Int J Mol Sci | 2024 | 39408908 | PubTator, text mining | PubMed |
| Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa. | Mol Ther Nucleic Acids | 2024 | 39391765 | PubTator, text mining | PubMed |
| The lncRNA SNHG26 drives the inflammatory-to-proliferative state transition of keratinocyte progenitor cells during wound healing. | Nat Commun | 2024 | 39366968 | PubTator, text mining | PubMed |
| Identification of Novel Anoikis-Related Gene Signatures to Predict the Prognosis, Immune Microenvironment, and Drug Sensitivity of Breast Cancer Patients. | Cancer Control | 2024 | 39340434 | PubTator, text mining | PubMed |
| Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC. | Pharmacol Res | 2024 | 39306019 | PubTator, text mining | PubMed |
| Identification and validation of diagnostic and prognostic biomarkers in prostate cancer based on WGCNA. | Discov Oncol | 2024 | 39304557 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3914/papers?page=4